FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Munshi Amit
2. Issuer Name and Ticker or Trading Symbol

ARENA PHARMACEUTICALS INC [ ARNA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President and CEO
(Last)          (First)          (Middle)

C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)

5/21/2020
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/21/2020  M(1)  50000 A$14.60 57750 D  
Common Stock 5/21/2020  S(1)  50000 D$55.00 7750 D  
Common Stock 5/22/2020  M(1)  34800 A$14.60 42550 D  
Common Stock 5/22/2020  S(1)  5390 D$56.6731 (2)37160 D  
Common Stock 5/22/2020  S(1)  9017 D$57.5205 (3)28143 D  
Common Stock 5/22/2020  S(1)  13931 D$58.6075 (4)14212 D  
Common Stock 5/22/2020  S(1)  6462 D$59.1174 (5)7750 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy) $14.60 5/21/2020  M (1)    50000   (6)2/13/2024 Common Stock 50000 $0.00 149800 D  
Employee Stock Option (right to buy) $14.60 5/22/2020  M (1)    34800   (6)2/13/2024 Common Stock 34800 $0.00 115000 D  

Explanation of Responses:
(1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
(2) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.19 to $56.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4, and 5 to this Form 4.
(3) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.07 to $57.97, inclusive.
(4) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97, inclusive.
(5) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.22, inclusive.
(6) The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Munshi Amit
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
X
President and CEO

Signatures
/s/ Andrew J. Cronauer, as Attorney-in-Fact5/22/2020
**Signature of Reporting PersonDate

Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more Arena Pharmaceuticals Charts.
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more Arena Pharmaceuticals Charts.